

AREA DRUG AND THERAPEUTICS COMMITTEE

Minutes of the meeting of the Area Drug and Therapeutics Committee held at 14:30 on Friday 6 December 2019 in Meeting Room 8, Waverley Gate, 2-4 Waterloo Place, Edinburgh, EH1 3EG.

Present: Professor S. Maxwell, Consultant Physician / Clinical Pharmacologist (Chair); Dr P. Bailey, Lothian Medical Committee Representative; Mrs J. Browning, Lead Pharmacist, Medicines Management Team; Mr A. Cameron, Community Pharmacist; Dr S. Clive, Chair of Cancer Therapeutics Advisory Committee; Ms M. Cuthbert, Associate Director of Pharmacy, Acute Services; Ms K. Davidson, Senior Pharmacist (Professional Secretary); Professor M. Eddleston, Professor of Clinical Toxicology; Dr M. Evans, Antimicrobial Team Clinical Lead; Ms S. Kerr, Lead Pharmacist, Western General Hospital; Ms M. McCulloch, Lead Nurse for Advancing Roles, LANMAC Representative; Ms M. Reid, Consultant in Pharmaceutical Public Health; Ms A. Wilson, Director of Pharmacy, NHS Borders (until 4pm) and Dr A. Watson, Psychiatrist, Chair of HSSMC.

In attendance: Mr S. McTaggart, Principal Pharmacist, Public Health and Intelligence, NSS (Item 5.1); Mr B. Hannan, HEPMA Pharmacist (Items 5.2 & 7.2) and Mr C. Graham, Corporate Governance Team, NHS Lothian (minutes);

Apologies: Mr S. McBurney, Associate Director of Pharmacy, Primary and Community Care, Mental Health & Associated Services; Dr R. McDermott, GP, Area Medical Committee Representative; Mr M. Hunter, Head of Primary Care Contracting Organisation, Finance and Professor A. Timoney, Director of Pharmacy, NHS Lothian (Vice Chair).

The Chair welcomed Members to the meeting.

1. Declaration of Interest

1.1 No declarations made.

2. Minutes from Previous Meetings

2.1 Minutes of ADTC 02/08/19 – approved.

2.2 Note of inquorate ADTC 04/10/19 – agreed.

- The Committee noted that most actions from 04/10/19 were now complete except for the 'Shared Care of Medicines review date' action which Ms Davidson would take forward with lead for shared care procedure.

KD

3. Matters Arising

3.1 None.

4. ADTC Work Programmes 2019 – 2020 & 2020 – 2021

- 4.1 Ms Davidson highlighted changes made to the 2020-2021 work programme. There was discussion on whether or not Quality Improvement should be a standing agenda item or whether people would attend on a rolling basis. There was also discussion on the annual update and presentation around SPSP, the Strategic Planning section of the work programme and the “national/regional” formulary. Ms Davidson would take suggestion on board and update and clarify the work programme for the next meeting.

KD

5. Safe and Effective Patient Care

- 5.1 Sodium Valproate Data Presentation - Mr McTaggart gave a presentation covering the Drug utilisation study examining the impact of the regulatory guidance issued on the prescribing of valproate to women of childbearing potential in NHS Scotland.

- 5.1.1 The presentation also covered antiepileptic drugs prescribing; analysis of prevalence of females aged 14-45 years in relation to MHRA guidance; NHS board variation in valproate prescribing prevalence; Co-prescribing of contraception with valproate.

- 5.1.2 There was discussion on how the drug was still being prescribed and the issues around this and how contraception prescriptions were captured on the system. It was noted that there was concern that the knock on effect was also a decline in prescribing in male patients and those not of child bearing potential.

- 5.1.3 The Chair thanked Mr McTaggart for the informative presentation.

- 5.2 Homecare Update - Mr Hannan updated the Committee on the provision of Medicines Homecare Services in NHS Lothian, most specifically with regard to the outcomes of the recent Integrated Impact Assessment undertaken for the service.

- 5.2.1 There was discussion on the minimal changes to policy drivers and the format; cost savings; what success for the Homecare Services looked like; how performance would be measured; community pharmacy involvement and the national audit which would hopefully be available for the February ADTC meeting.

- 5.2.2 The Committee agreed to support the findings of the Integrated Impact Assessment undertaken on 14th August 2019. It was also noted that Mr Cameron would be invited to join the Homecare Governance Group to provide community pharmacy input.

- 5.3 Scottish Patient Safety Programme/Safer Medicines (primary and secondary care) Annual update - The circulated update from Dr Veiraiah was noted. The Chair and Professor Eddleston would contact Dr Veiraiah and ask him to come along to present to the Committee.

SM/MEdd

- 5.4 Antimicrobial Management Team Update - Dr Evans gave a presentation on the work of the Antimicrobial Management Committee. The presentation covered the Scottish Government Standards on Healthcare Associated Infections and Indicators on Antibiotic Use; the WHO/PHE AWaRe LIST; the Primary Care Stewardship Programme; the Surgical Stewardship Programme and the proportion of parenteral/non parenteral DDDs issued by quarter for RIE, WGH and SJH. There was also discussion on the resource and size of the Antimicrobial Management Team; quality improvement projects; senior engagement and the improvement work with wards.

6. Effective Use of Resources

- 6.1 MURG – Confirmation of New Chair & Quarterly Reports – No update received.

7. Strategic Planning

- 7.1 Electronic Prescribing Primary Care - Ms Browning reminded the Committee of previous discussion on the ability to have eLJF clinical in the new GP prescribing system. Ms Browning reassured the Committee that there would be no expected loss of functionality with the new system however the implementation timeline had already been significantly delayed.

- 7.2 Electronic Prescribing Secondary Care - Mr Hannan gave a high level update presentation around HEPMA covering the Governance Structure and the HEPMA Programme Update (Technical Activities, Software Build and Roll out). There was discussion around clinical prescribing input; the programme board and strong clinical leadership. It was noted that the terms of reference were to be circulated; that Mr D. Clifford would be taking over Mr Hannan's role from February 2020 and REAS representation on the programme board was to be progressed.

- 7.2.1 The Committee noted that this was a large piece of work and the timescales could not yet be defined.

- 7.2.2 The Chair thanked Mr Hannan for the update and recognised that this would be the last ADTC meeting he would attend before leaving his role.

- 7.3 High Level Principles for Good Practice in Remote Consultations and Prescribing - The Chair stated that it was useful to highlight the guidance on this area which was likely to continue to grow as an issue.

KD

- 7.4 Health and Sport Committee, Supply and Demand for Medicines Submission – The Committee noted the response that had been submitted.

8. Working in Partnership

- 8.1 Scottish Medicines Consortium: Patient Access Scheme + Primary Care Rebate Scheme NHS Lothian Annual Report – The Committee noted that the report had not been submitted by Mr Hunter and the item would be prepared for the February ADTC meeting

MH

8.2 ADTC Constitution - Ms Davidson reported that the ADTC constitution was now at its review date. Ms Davidson and Ms Browning had reviewed the constitution with a view to aligning it with the ADTCC standard proforma terms of reference template. Any gaps or missing areas had been highlighted in the attached appendix to the paper for the Committee's consideration, ideas and agreement.

8.2.1 There was discussion on areas of the current constitution that may now be devolved elsewhere and the need to clarify the best reporting mechanism to provide assurance to the Board's Healthcare Governance Committee. It was noted that the flowchart in the constitution needed to be updated.

8.2.2 There was also discussion on the provision to establish short life working groups of the Committee; membership and election of members; extraordinary meetings and chair's action; membership skill mix and the Committee quorum requirements.

8.2.3 Ms Davidson would update the Constitution which would come for further review and sign off at the February 2020 ADTC Meeting.

KD

8.3 Scottish Medicine Consortium: SMC

8.3.1 SMC Call for Membership - The Committee noted no nominations had been put forward however that at this time it was felt that there was sufficient ADTC representation from NHS Lothian on SMC

8.3.2 Changes to SMC Advice - Ms Browning updated the Committee on changes being made to streamline SMC processes. The changes were around what SMC would and would not now be looking at or reviewing, this included a fast-track resubmission process if the only change is a new or improved Patient Access Scheme (PAS) and also paediatric licence extensions". Concerns had been raised about the paediatric process through ADTCC.

8.3.2.1 It was agreed that Ms Browning would prepare correspondence for the ADTC Chair to review and send expressing concerns around the proposals.

8.3.3 Position Statement on Prescribing of Branded Generics - There was discussion on the renewal of the position statement. It was noted that not all health boards took a similar position regarding branded generics and this had potential for destabilising pricing.

8.3.3.1 It was agreed to support and continue NHS Lothian's position but to also enquire further to ascertain if there is further national position statements from Scottish Governments and Community Pharmacy Scotland. The concerns would also be taken back as an issue to ADTCC.

8.3.3.2 The position statement was agreed subject to the word "Patient" being changed to 'Patent'.

JB/KD

8.4 ADTC Collaboration (HIS) update – The recent ADTCC newsletter had been circulated and the Webex sessions continue.

8.5 ADTC Policies and Procedures – Development and Review – It was noted that the work to develop and review the policies and procedures online remained in progress.

8.6 SACT Consent Guidance 2019 Key Stakeholder Consultation – It was noted that CTAC were responding to the consultation and this had been discussed at the CTAC meeting last week.

9. Minutes from Committees and Division

9.1 The Committee noted the following minutes from Committees and Division:

- Formulary Committee, 02 October 2019
- UHD Drug and Therapeutics Committee, 28 August 2019
- Paediatric & Neonatal Drug & Therapeutics Committee, 31 May 2019 & 26 July 2019
- Hospital and Specialist Services Medicines Committee, 11 September 2019
- Medicines Policies Sub Committee, 19 September 2019
- Medicines Homecare Governance Group, 24 June 2019

10. Any Other Competent Business

10.1 There was no other business.

11. Date of Next Meeting

11.1 The next meeting of the Area Drug and Therapeutics Committee would take place at **14.30 on Friday 7 February 2020 in Meeting Room 8**, Fifth Floor, Waverley Gate.

12. Future Meeting Dates

- 07 February 2020
- 03 April 2020
- 05 June 2020
- 07 August 2020
- 02 October 2020
- 04 December 2020